Optibrium secures seed investment from Kester Capital to fund expansion
Kester Capital provides further backing to accelerate the development of computer-aided drug discovery technologies.
Optibrium develops software for drug discovery and small molecule design. Its platform empowers research teams with predictive modelling and artificial intelligence tools.
Optibrium has secured a seed investment from existing backer Kester Capital to support its continued commercial expansion. The funds will be directed towards further developing its computer-aided drug discovery technologies, bolstering the senior leadership team, and expanding operations across Europe and the United States following a recent office relocation in Cambridge. This latest backing follows an initial injection from Kester Capital in February 2021, underpinned by three years of consistent annual recurring revenue growth exceeding 25 percent.
From the founder
"It’s been an incredible year, with Kester Capital’s original investment affording us the opportunity to take the company to new heights as we successfully launched Cerella, our ground-breaking new AI platform, and actioned ambitious plans to grow the company. I am delighted that due to this success, Kester is investing further and their continued support will allow us to accelerate our product development plans and further capitalise on the substantial market opportunities."
Matt Segall
CEO at Optibrium
Investor perspective
"Optibrium’s cutting edge software continues to drive some of the most exciting developments within computer-aided drug discovery. In the last year, we have been tremendously impressed by Optibrium’s ingenuity and the business’ achievements. We also appreciate the talent and expertise demonstrated by the team as the business continues to thrive."
Adam Maidment
Managing Partner, Kester Capital
Use of funds
- 01Continue product development
- 02Grow the team
- 03Expand into international markets
